{"links":{"self":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news","first":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news?page=1","next":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news?page=2","prev":null,"last":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news?page=2"},"meta":{"executionDate":"2024-07-26T05:23:02","cmsDomain":"http://investors.akoyabio.com","count":100},"data":[{"id":9171,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9171","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-report-second-quarter-2024-financial-results"},"title":"Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024.","language":"en","releaseDate":{"dateUTC":"2024-07-15T20:00:11","date":"2024-07-15T16:00:11","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9171/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-07-15T20:00:12","lastUpdatedUTC":"2024-07-15T20:00:12"},{"id":9076,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9076","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-reports-first-quarter-2024-financial-results"},"title":"Akoya Biosciences Reports First Quarter 2024 Financial Results ","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the first quarter ending March 31, 2024. Business Highlights Revenue was $18.4 million in the first quarter of 2024,","language":"en","releaseDate":{"dateUTC":"2024-05-13T20:00:28","date":"2024-05-13T16:00:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Reports First Quarter 2024 Financial Results ","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9076/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-13T20:00:36","lastUpdatedUTC":"2024-05-13T20:00:36"},{"id":9061,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9061","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-and-neracare-enter-exclusive-agreement-enable"},"title":"Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients","type":{"title":"General","id":3886},"teaser":"Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. MARLBOROUGH, Mass.","language":"en","releaseDate":{"dateUTC":"2024-05-09T12:00:41","date":"2024-05-09T08:00:41","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9061/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-09T12:00:51","lastUpdatedUTC":"2024-05-09T12:00:51"},{"id":9051,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9051","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-opens-operations-and-manufacturing-center"},"title":"Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company ® , has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the","language":"en","releaseDate":{"dateUTC":"2024-05-06T12:00:33","date":"2024-05-06T08:00:33","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9051/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-06T12:00:36","lastUpdatedUTC":"2024-05-06T12:00:36"},{"id":9041,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9041","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-and-shanghai-kr-pharmtech-announce-chinese"},"title":"Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows","type":{"title":"General","id":3886},"teaser":"KR-HT5 is based on Akoya’s PhenoImager® HT Platform MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company ® , and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have","language":"en","releaseDate":{"dateUTC":"2024-05-02T12:01:00","date":"2024-05-02T08:01:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9041/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-02T12:01:06","lastUpdatedUTC":"2024-05-02T12:01:06"},{"id":9001,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9001","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-first-quarter-2024-financial-results-may-13th-2024"},"title":"Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the first quarter of 2024 after the market close on May 13 th , 2024.","language":"en","releaseDate":{"dateUTC":"2024-04-22T20:05:09","date":"2024-04-22T16:05:09","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/9001/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-04-22T20:05:16","lastUpdatedUTC":"2024-04-22T20:05:16"},{"id":8991,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8991","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-showcases-spatial-biology-20-solutions-aacr"},"title":"Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the","language":"en","releaseDate":{"dateUTC":"2024-04-05T12:00:33","date":"2024-04-05T08:00:33","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8991/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-04-05T12:00:42","lastUpdatedUTC":"2024-04-05T12:00:42"},{"id":8916,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8916","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-record-revenue-fourth-quarter-2023-and-provides"},"title":"Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook","type":{"title":"General","id":3886},"teaser":"Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®,","language":"en","releaseDate":{"dateUTC":"2024-03-04T21:05:30","date":"2024-03-04T16:05:30","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8916/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-03-04T21:05:37","lastUpdatedUTC":"2024-03-04T21:05:37"},{"id":8861,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8861","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-fourth-quarter-and-full-year-2023-financial-results"},"title":"Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4 th , 2024.","language":"en","releaseDate":{"dateUTC":"2024-02-08T21:05:30","date":"2024-02-08T16:05:30","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8861/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-02-08T21:05:47","lastUpdatedUTC":"2024-02-08T21:05:47"},{"id":8841,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8841","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-technology-enables-queensland-spatial-biology"},"title":"Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases","type":{"title":"General","id":3886},"teaser":"PhenoCycler®-Fusion system selected as the Centre’s platform technology for advanced spatial biology studies MARLBOROUGH, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company ® , today announced that the newly established Queensland Spatial","language":"en","releaseDate":{"dateUTC":"2024-01-18T13:00:23","date":"2024-01-18T08:00:23","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8841/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-01-18T13:00:26","lastUpdatedUTC":"2024-01-18T13:00:26"},{"id":8816,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8816","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-garry-nolan-phd-james-allison-phd"},"title":"Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board","type":{"title":"General","id":3886},"teaser":"Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya’s spatial biology solutions MARLBOROUGH, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial","language":"en","releaseDate":{"dateUTC":"2024-01-10T13:00:48","date":"2024-01-10T08:00:48","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8816/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-01-10T13:00:58","lastUpdatedUTC":"2024-01-10T13:00:58"},{"id":8801,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8801","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-and-thermo-fisher-scientific-announce-license"},"title":"Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow","type":{"title":"General","id":3886},"teaser":"The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology","language":"en","releaseDate":{"dateUTC":"2024-01-07T13:00:51","date":"2024-01-07T08:00:51","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8801/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-01-07T13:00:57","lastUpdatedUTC":"2024-01-07T13:00:57"},{"id":8791,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8791","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-preliminary-financial-results-fourth"},"title":"Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023 cash, cash equivalents, and","language":"en","releaseDate":{"dateUTC":"2024-01-07T13:00:50","date":"2024-01-07T08:00:50","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8791/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-01-07T13:00:56","lastUpdatedUTC":"2024-01-07T13:00:56"},{"id":8796,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8796","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-deploys-maxfuse-algorithm-co-developed-dr"},"title":"Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform","type":{"title":"General","id":3886},"teaser":"MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities Development and application of MaxFuse were described in two recent Nature publications MARLBOROUGH, Mass., Jan.","language":"en","releaseDate":{"dateUTC":"2024-01-07T13:00:50","date":"2024-01-07T08:00:50","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8796/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-01-07T13:00:56","lastUpdatedUTC":"2024-01-07T13:00:56"},{"id":8751,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8751","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-42nd-annual-jp-morgan-healthcare-conference"},"title":"Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in the 42 nd Annual J.P. Morgan Healthcare Conference. Brian McKelligon, CEO, is scheduled to present on Wednesday,","language":"en","releaseDate":{"dateUTC":"2023-12-20T13:05:28","date":"2023-12-20T08:05:28","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8751/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-12-20T13:05:33","lastUpdatedUTC":"2023-12-20T13:05:33"},{"id":8701,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8701","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-record-revenue-third-quarter-2023-and-reiterates"},"title":"Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance","type":{"title":"General","id":3886},"teaser":"Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the third","language":"en","releaseDate":{"dateUTC":"2023-11-08T21:00:30","date":"2023-11-08T16:00:30","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8701/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-11-08T21:00:34","lastUpdatedUTC":"2023-11-08T21:00:34"},{"id":8671,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8671","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-three-upcoming-investor-conferences-2"},"title":"Akoya to Participate at Three Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences. Stephens Annual Investment Conference | NASH 2023 Fireside Chat","language":"en","releaseDate":{"dateUTC":"2023-11-02T12:01:19","date":"2023-11-02T08:01:19","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at Three Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8671/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-11-02T12:01:30","lastUpdatedUTC":"2023-11-02T12:01:30"},{"id":8661,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8661","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-showcase-new-spatial-biology-20-solutions-and"},"title":"Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023","type":{"title":"General","id":3886},"teaser":"Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya’s spatial phenotyping solutions will also exhibit at SITC MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq:","language":"en","releaseDate":{"dateUTC":"2023-10-31T13:01:19","date":"2023-10-31T09:01:19","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8661/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-31T13:01:20","lastUpdatedUTC":"2023-10-31T13:01:20"},{"id":8656,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8656","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-peer-reviewed-publication-using"},"title":"Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The University of Queensland’s Frazer Institute have comprehensively mapped the spatial proteome of head","language":"en","releaseDate":{"dateUTC":"2023-10-17T14:23:36","date":"2023-10-17T10:23:36","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8656/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-17T14:23:45","lastUpdatedUTC":"2023-10-17T14:23:45"},{"id":8641,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8641","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-third-quarter-2023-financial-results-november-8th"},"title":"Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of 2023 after the market close on November 8 th , 2023.","language":"en","releaseDate":{"dateUTC":"2023-10-11T20:05:29","date":"2023-10-11T16:05:29","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8641/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-11T20:05:40","lastUpdatedUTC":"2023-10-11T20:05:40"},{"id":8621,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8621","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-sets-new-standard-scaling-spatial-biology"},"title":"Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms","type":{"title":"General","id":3886},"teaser":"PhenoCycler-Fusion 2.0 enhancements enable the highest throughput workflow for spatial discovery studies. PhenoImager HT 2.0 delivers a 5x greater speed improvement for spatial studies in translational and clinical research. MARLBOROUGH, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences,","language":"en","releaseDate":{"dateUTC":"2023-09-19T12:00:37","date":"2023-09-19T08:00:37","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8621/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-09-19T12:00:45","lastUpdatedUTC":"2023-09-19T12:00:45"},{"id":8596,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8596","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-record-revenue-second-quarter-2023-and-reiterates"},"title":"Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance","type":{"title":"General","id":3886},"teaser":"Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second","language":"en","releaseDate":{"dateUTC":"2023-08-07T20:06:30","date":"2023-08-07T16:06:30","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8596/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-08-07T20:06:33","lastUpdatedUTC":"2023-08-07T20:06:33"},{"id":8576,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8576","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-milestone-1000-peer-reviewed"},"title":"Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced a momentous achievement - publication of the 1,000 th peer-reviewed article citing use of the company’s technology, the largest publication volume in","language":"en","releaseDate":{"dateUTC":"2023-08-07T12:05:49","date":"2023-08-07T08:05:49","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8576/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-08-07T12:05:50","lastUpdatedUTC":"2023-08-07T12:05:50"},{"id":8556,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8556","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-three-upcoming-investor-conferences-1"},"title":"Akoya to Participate at Three Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that Company management will be participating in three upcoming investor conferences. Canaccord 43 rd Annual Growth Conference Fireside Chat on","language":"en","releaseDate":{"dateUTC":"2023-07-26T20:06:06","date":"2023-07-26T16:06:06","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at Three Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8556/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-07-26T20:06:09","lastUpdatedUTC":"2023-07-26T20:06:09"},{"id":8526,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8526","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-second-quarter-2023-financial-results-august-7th"},"title":"Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the second quarter of 2023 after the market close on Monday, August 7 th , 2023.","language":"en","releaseDate":{"dateUTC":"2023-07-12T12:05:48","date":"2023-07-12T08:05:48","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8526/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-07-12T12:05:53","lastUpdatedUTC":"2023-07-12T12:05:53"},{"id":8441,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8441","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-two-upcoming-investor-conferences-0"},"title":"Akoya to Participate at Two Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that Company management will be participating in two upcoming investor conferences. Capital One Securities 2 nd Annual Spatial Biology and","language":"en","releaseDate":{"dateUTC":"2023-06-12T20:05:56","date":"2023-06-12T16:05:56","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at Two Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8441/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-06-12T20:05:59","lastUpdatedUTC":"2023-06-12T20:05:59"},{"id":8426,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8426","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-pricing-public-offering-common-stock"},"title":"Akoya Biosciences Announces Pricing of Public Offering of Common Stock","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its public offering of 8,700,000 shares of common stock (the “Offering”) at a public offering price of $5.00 per share for gross","language":"en","releaseDate":{"dateUTC":"2023-06-08T04:56:31","date":"2023-06-08T00:56:31","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Pricing of Public Offering of Common Stock","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8426/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-06-08T04:56:35","lastUpdatedUTC":"2023-06-08T04:56:35"},{"id":8411,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8411","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-public-offering-common-stock"},"title":"Akoya Biosciences Announces Public Offering of Common Stock","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has launched an underwritten public offering of shares of its common stock (the “Offering”). In addition, Akoya expects to grant the underwriters","language":"en","releaseDate":{"dateUTC":"2023-06-07T20:08:55","date":"2023-06-07T16:08:55","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Public Offering of Common Stock","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8411/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-06-07T20:08:56","lastUpdatedUTC":"2023-06-07T20:08:56"},{"id":8306,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8306","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-record-revenue-first-quarter-2023-and-reiterates"},"title":"Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance","type":{"title":"General","id":3886},"teaser":"Q1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter","language":"en","releaseDate":{"dateUTC":"2023-05-08T20:05:29","date":"2023-05-08T16:05:29","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8306/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-08T20:05:34","lastUpdatedUTC":"2023-05-08T20:05:34"},{"id":8291,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8291","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-marks-milestone-achievement-shipment-1000th"},"title":"Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has shipped it’s 1,000 th instrument, a significant milestone for the company and the largest installed base in the spatial biology industry.","language":"en","releaseDate":{"dateUTC":"2023-04-27T12:00:12","date":"2023-04-27T08:00:12","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8291/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-04-27T12:00:12","lastUpdatedUTC":"2023-04-27T12:00:12"},{"id":8271,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8271","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-and-enable-medicine-introduce-cloud-platform"},"title":"Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data","type":{"title":"General","id":3886},"teaser":"Enable Cloud Platform trained on high plex spatial imaging datasets across 20,000 samples run on the PhenoCycler ® System Commercial launch at AACR 2023 Annual Meeting (Akoya booth #1713) MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc.","language":"en","releaseDate":{"dateUTC":"2023-04-12T12:01:22","date":"2023-04-12T08:01:22","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8271/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-04-12T12:01:32","lastUpdatedUTC":"2023-04-12T12:01:32"},{"id":8266,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8266","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-introduces-phenocode-discovery-panels-simplify"},"title":"Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow","type":{"title":"General","id":3886},"teaser":"Modular panel design sets foundation for continued expansion of applications on the PhenoCycler ® -Fusion system First protein panel commercially available at AACR 2023 Annual Meeting and first RNA panel to launch in H2 2023 MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences,","language":"en","releaseDate":{"dateUTC":"2023-04-12T12:00:50","date":"2023-04-12T08:00:50","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8266/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-04-12T12:00:52","lastUpdatedUTC":"2023-04-12T12:00:52"},{"id":8241,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8241","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-first-quarter-2023-financial-results-may-8th-2023"},"title":"Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8 th , 2023.","language":"en","releaseDate":{"dateUTC":"2023-04-06T12:00:36","date":"2023-04-06T08:00:36","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8241/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-04-06T12:00:41","lastUpdatedUTC":"2023-04-06T12:00:41"},{"id":8191,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8191","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-leadership-transition"},"title":"Akoya Biosciences Announces Leadership Transition","type":{"title":"General","id":3886},"teaser":"Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that","language":"en","releaseDate":{"dateUTC":"2023-03-20T20:00:30","date":"2023-03-20T16:00:30","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Leadership Transition","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8191/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-03-20T20:00:34","lastUpdatedUTC":"2023-03-20T20:00:34"},{"id":8151,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8151","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-record-revenue-fourth-quarter-2022-and-provides"},"title":"Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance","type":{"title":"General","id":3886},"teaser":"Q4 2022 revenue $21.2 million and FY 2022 revenue $74.9 million FY 2023 revenue guidance range $95-98 million MARLBOROUGH, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the fourth","language":"en","releaseDate":{"dateUTC":"2023-03-06T21:05:50","date":"2023-03-06T16:05:50","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8151/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-03-06T21:06:04","lastUpdatedUTC":"2023-03-06T21:06:04"},{"id":8131,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8131","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-appointment-jennifer-kamocsay"},"title":"Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and","language":"en","releaseDate":{"dateUTC":"2023-02-28T13:02:03","date":"2023-02-28T08:02:03","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8131/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-28T13:02:07","lastUpdatedUTC":"2023-02-28T13:02:07"},{"id":8071,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8071","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-fourth-quarter-and-full-year-2022-financial-results"},"title":"Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Monday, March 6 th , 2023.","language":"en","releaseDate":{"dateUTC":"2023-02-06T13:05:28","date":"2023-02-06T08:05:28","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8071/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-06T13:05:31","lastUpdatedUTC":"2023-02-06T13:05:31"},{"id":8046,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8046","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-present-first-its-kind-spatial-multiomics"},"title":"Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting","type":{"title":"General","id":3886},"teaser":"Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company’s multiomics solution MARLBOROUGH, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® ,","language":"en","releaseDate":{"dateUTC":"2023-02-01T13:01:15","date":"2023-02-01T08:01:15","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8046/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-01T13:01:22","lastUpdatedUTC":"2023-02-01T13:01:22"},{"id":8026,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8026","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-announces-preliminary-financial-results-fourth-quarter-0"},"title":"Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022. Akoya reported the following preliminary financial","language":"en","releaseDate":{"dateUTC":"2023-01-08T21:00:27","date":"2023-01-08T16:00:27","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8026/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-08T21:00:34","lastUpdatedUTC":"2023-01-08T21:00:34"},{"id":8016,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8016","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/agilent-and-akoya-biosciences-announce-partnership-drive"},"title":"Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications","type":{"title":"General","id":3886},"teaser":"Will commercialize end-to-end workflow solutions for tissue biomarker analysis in companion diagnostic development SANTA CLARA, Calif , & MARLBOROUGH, Mass. --(BUSINESS WIRE)--Jan. 6, 2023-- Agilent Technologies, Inc. (NYSE: A) today announced a partnership with Akoya Biosciences, Inc.","language":"en","releaseDate":{"dateUTC":"2023-01-06T13:00:00","date":"2023-01-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8016/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-06T13:00:16","lastUpdatedUTC":"2023-01-06T13:30:37"},{"id":8006,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8006","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-41st-annual-jp-morgan-healthcare-conference"},"title":"Akoya to Participate at 41st Annual J.P. Morgan Healthcare Conference","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will be participating in the 41 st Annual J.P. Morgan Healthcare Conference. Brian McKelligon, CEO, is scheduled to present on Wednesday,","language":"en","releaseDate":{"dateUTC":"2022-12-28T21:00:28","date":"2022-12-28T16:00:28","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at 41st Annual J.P. Morgan Healthcare Conference","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/8006/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-12-28T21:00:32","lastUpdatedUTC":"2022-12-28T21:00:32"},{"id":7961,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7961","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-showcases-latest-spatial-biology-innovations"},"title":"Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day","type":{"title":"General","id":3886},"teaser":"New products and partnerships further accelerate and simplify identification of actionable spatial signatures, creating unprecedented opportunities to improve patient outcomes Ready-to-use panels, turnkey software solutions, and instrument enhancements put more power in the hands of spatial biology","language":"en","releaseDate":{"dateUTC":"2022-12-15T21:00:12","date":"2022-12-15T16:00:12","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7961/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-12-15T21:00:17","lastUpdatedUTC":"2022-12-15T21:00:17"},{"id":7896,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7896","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-launches-phenocode-signature-panels-accelerate"},"title":"Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy","type":{"title":"General","id":3886},"teaser":"Each panel focuses on distinct areas of tumor biology and response to therapy which are of greatest interest to translational and clinical researchers Simplifies biomarker assay development and validation Creates end-to-end spatial phenotyping workflow when integrated with the PhenoImager platforms","language":"en","releaseDate":{"dateUTC":"2022-11-07T21:06:32","date":"2022-11-07T16:06:32","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7896/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-07T21:06:40","lastUpdatedUTC":"2022-11-07T21:06:40"},{"id":7881,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7881","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-record-revenue-40-yoy-growth-third-quarter-and"},"title":"Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance","type":{"title":"General","id":3886},"teaser":"Q3 2022 revenue $18.9 million, 40% y/y growth Raising FY 2022 revenue guidance range to $73-75 million MARLBOROUGH, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter","language":"en","releaseDate":{"dateUTC":"2022-11-07T21:05:32","date":"2022-11-07T16:05:32","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7881/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-07T21:05:41","lastUpdatedUTC":"2022-11-07T21:05:41"},{"id":7861,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7861","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-three-upcoming-investor-conferences-0"},"title":"Akoya to Participate at Three Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will be participating in three upcoming investor conferences. Stephens Annual Investment Conference (Nashville, TN) Fireside Chat on","language":"en","releaseDate":{"dateUTC":"2022-11-03T12:05:10","date":"2022-11-03T08:05:10","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at Three Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7861/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-03T12:05:14","lastUpdatedUTC":"2022-11-03T12:05:14"},{"id":7831,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7831","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-third-quarter-2022-financial-results-november-7th"},"title":"Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7 th , 2022.","language":"en","releaseDate":{"dateUTC":"2022-10-11T12:05:28","date":"2022-10-11T08:05:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7831/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-10-11T12:05:32","lastUpdatedUTC":"2022-10-11T12:05:32"},{"id":7761,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7761","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-four-upcoming-investor-conferences"},"title":"Akoya to Participate at Four Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming investor conferences. H.C. Wainwright 24 th Annual Global Investment Conference (New York, NY)","language":"en","releaseDate":{"dateUTC":"2022-08-31T12:05:28","date":"2022-08-31T08:05:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at Four Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7761/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-31T12:05:33","lastUpdatedUTC":"2022-08-31T12:05:33"},{"id":7721,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7721","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-second-quarter-2022-operating-results-and-raises"},"title":"Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance","type":{"title":"General","id":3886},"teaser":"Q2 2022 revenue $17.9 million, 37% y/y growth Raising FY 2022 revenue guidance range to $71-74 million MARLBOROUGH, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter","language":"en","releaseDate":{"dateUTC":"2022-08-08T20:06:22","date":"2022-08-08T16:06:22","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7721/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-08T20:06:28","lastUpdatedUTC":"2022-08-08T20:06:28"},{"id":7696,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7696","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-two-upcoming-investor-conferences"},"title":"Akoya to Participate at Two Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will be participating in two upcoming investor conferences. UBS Genomics 2.0 and MedTech Innovation Conference Fireside Chat – Brian","language":"en","releaseDate":{"dateUTC":"2022-07-27T12:05:48","date":"2022-07-27T08:05:48","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at Two Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7696/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-07-27T12:05:57","lastUpdatedUTC":"2022-07-27T12:05:57"},{"id":7671,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7671","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-second-quarter-2022-financial-results-august-8th"},"title":"Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2022 after the market close on Monday, August 8 th , 2022.","language":"en","releaseDate":{"dateUTC":"2022-07-12T12:05:28","date":"2022-07-12T08:05:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7671/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-07-12T12:05:31","lastUpdatedUTC":"2022-07-12T12:05:31"},{"id":7666,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7666","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-partner-acrivon-therapeutics-clinical"},"title":"Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic","type":{"title":"General","id":3886},"teaser":"The OncoSignature ® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers The OncoSignature ® test will run on Akoya’s PhenoImager™ Solution","language":"en","releaseDate":{"dateUTC":"2022-06-28T12:05:49","date":"2022-06-28T08:05:49","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7666/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-28T12:05:59","lastUpdatedUTC":"2022-06-28T12:05:59"},{"id":7606,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7606","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-highlight-novel-spatial-transcriptomics"},"title":"Akoya Biosciences to Highlight Novel Spatial Transcriptomics Capabilities on PhenoCycler-Fusion at AGBT 2022 Annual Meeting","type":{"title":"General","id":3886},"teaser":"PhenoCycler™-Fusion will enable single-cell, whole-slide spatial multiomic capabilities on a single platform MARLBOROUGH, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company ® , will present for the first time, data generated using its","language":"en","releaseDate":{"dateUTC":"2022-06-01T12:05:29","date":"2022-06-01T08:05:29","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Highlight Novel Spatial Transcriptomics Capabilities on PhenoCycler-Fusion at AGBT 2022 Annual Meeting","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7606/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-01T12:05:32","lastUpdatedUTC":"2022-06-01T12:05:32"},{"id":7581,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7581","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-first-quarter-2022-operating-results-and-raises"},"title":"Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance","type":{"title":"General","id":3886},"teaser":"Q1 2022 revenue $16.9 million, 38% growth over prior year period Raising FY 2022 revenue guidance range to $70-73 million MARLBOROUGH, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for","language":"en","releaseDate":{"dateUTC":"2022-05-05T20:06:23","date":"2022-05-05T16:06:23","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7581/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-05T20:06:33","lastUpdatedUTC":"2022-05-05T20:06:33"},{"id":7566,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7566","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-three-upcoming-investor-conferences"},"title":"Akoya to Participate at Three Upcoming Investor Conferences","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in three upcoming investor conferences. Bank of America 2022 Healthcare Conference Presentation on Tuesday, May 10 th at","language":"en","releaseDate":{"dateUTC":"2022-05-03T12:05:49","date":"2022-05-03T08:05:49","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at Three Upcoming Investor Conferences","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7566/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-03T12:05:54","lastUpdatedUTC":"2022-05-03T12:05:54"},{"id":7521,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7521","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-ehab-el-gabry-md-chief-medical"},"title":"Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer","type":{"title":"General","id":3886},"teaser":"Dr. El-Gabry’s extensive leadership experience will be critical to accelerating Akoya’s groundbreaking spatial biomarker research technologies into clinical tools that will impact patient care MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The","language":"en","releaseDate":{"dateUTC":"2022-04-19T12:05:28","date":"2022-04-19T08:05:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7521/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-19T12:05:34","lastUpdatedUTC":"2022-04-19T12:05:34"},{"id":7486,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7486","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-first-quarter-2022-financial-results-may-5th-2022"},"title":"Akoya to Report First Quarter 2022 Financial Results on May 5th, 2022","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5 th , 2022.","language":"en","releaseDate":{"dateUTC":"2022-04-14T12:05:28","date":"2022-04-14T08:05:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report First Quarter 2022 Financial Results on May 5th, 2022","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7486/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-14T12:05:38","lastUpdatedUTC":"2022-04-14T12:05:38"},{"id":7476,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7476","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-showcase-new-data-phenocycler-fusion-aacr"},"title":"Akoya Biosciences to Showcase New Data on PhenoCycler-Fusion at the AACR Annual Meeting 2022","type":{"title":"General","id":3886},"teaser":"Company to present industry’s first 100-plex, whole slide dataset for deep spatial phenotyping of the tumor microenvironment The Company will also showcase its novel protein chemistry to accelerate biomarker validation MARLBOROUGH, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc.,","language":"en","releaseDate":{"dateUTC":"2022-04-06T12:05:28","date":"2022-04-06T08:05:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Showcase New Data on PhenoCycler-Fusion at the AACR Annual Meeting 2022","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7476/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-06T12:05:58","lastUpdatedUTC":"2022-04-06T12:05:58"},{"id":7421,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7421","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-fourth-quarter-and-full-year-2021-operating"},"title":"Akoya Reports Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook","type":{"title":"General","id":3886},"teaser":"Q4 2021 revenue $16.2 million and FY 2021 revenue $54.9 million FY 2022 revenue guidance $69 - 71 million MARLBOROUGH, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth","language":"en","releaseDate":{"dateUTC":"2022-03-14T20:05:07","date":"2022-03-14T16:05:07","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7421/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-14T20:06:01","lastUpdatedUTC":"2022-03-14T20:06:01"},{"id":7391,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7391","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-fourth-quarter-and-full-year-2021-financial-results"},"title":"Akoya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14th, 2022 and Present at the Cowen Annual Health Care Conference on March 8th, 2022","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Monday, March 14 th , 2022.","language":"en","releaseDate":{"dateUTC":"2022-02-22T13:00:28","date":"2022-02-22T08:00:28","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14th, 2022 and Present at the Cowen Annual Health Care Conference on March 8th, 2022","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7391/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-22T13:00:54","lastUpdatedUTC":"2022-02-22T13:00:54"},{"id":7376,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7376","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-present-btig-medtech-digital-health-life"},"title":"Akoya Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will be virtually participating in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.","language":"en","releaseDate":{"dateUTC":"2022-02-03T13:00:42","date":"2022-02-03T08:00:42","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7376/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-03T13:01:04","lastUpdatedUTC":"2022-02-03T13:01:04"},{"id":7356,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7356","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-appoints-marilee-moy-chief-people-officer"},"title":"Akoya Biosciences Appoints Marilee Moy as Chief People Officer","type":{"title":"General","id":3886},"teaser":"Ms. Moy brings 30 years of HR leadership experience at high-performing companies MARLBOROUGH, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced the appointment of Marilee Moy as Chief People Officer. Ms.","language":"en","releaseDate":{"dateUTC":"2022-01-20T13:05:47","date":"2022-01-20T08:05:47","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Appoints Marilee Moy as Chief People Officer","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7356/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-20T13:05:50","lastUpdatedUTC":"2022-01-20T13:05:50"},{"id":7341,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7341","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-commercial-launch-phenocycler-fusion"},"title":"Akoya Biosciences Announces Commercial Launch of  PhenoCycler-Fusion, the Fastest Single-Cell Spatial Biology System","type":{"title":"General","id":3886},"teaser":"Powered by novel technology that can map a million cells in 10 minutes, the system enables unbiased spatial discovery across whole slides, at scale MARLBOROUGH, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced the","language":"en","releaseDate":{"dateUTC":"2022-01-13T13:05:31","date":"2022-01-13T08:05:31","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Commercial Launch of  PhenoCycler-Fusion, the Fastest Single-Cell Spatial Biology System","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7341/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-13T13:05:34","lastUpdatedUTC":"2022-01-13T13:05:34"},{"id":7311,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7311","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-announces-preliminary-financial-results-fourth-quarter-and"},"title":"Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021. Akoya reported the following preliminary financial","language":"en","releaseDate":{"dateUTC":"2022-01-10T13:01:02","date":"2022-01-10T08:01:02","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7311/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-10T13:01:10","lastUpdatedUTC":"2022-01-10T13:01:10"},{"id":7296,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7296","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-and-bio-techne-partner-deliver-automated"},"title":"Akoya Biosciences and Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution","type":{"title":"General","id":3886},"teaser":"Akoya’s powerful new PhenoCycler™-Fusion system combined with Bio-Techne’s proven and established RNAScope® technology will enable comprehensive spatial phenotyping of RNA and protein biomarkers MARLBOROUGH, Mass. and MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:","language":"en","releaseDate":{"dateUTC":"2022-01-05T12:00:08","date":"2022-01-05T07:00:08","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences and Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7296/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-05T12:00:15","lastUpdatedUTC":"2022-01-05T12:00:15"},{"id":7286,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7286","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-present-40th-annual-jp-morgan-healthcare"},"title":"Akoya Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will be virtually participating in the 40 th Annual J.P. Morgan Healthcare Conference. Brian McKelligon, CEO, is scheduled to present on","language":"en","releaseDate":{"dateUTC":"2022-01-04T13:05:28","date":"2022-01-04T08:05:28","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7286/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-04T13:05:35","lastUpdatedUTC":"2022-01-04T13:05:35"},{"id":7266,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7266","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-unveils-comprehensive-roadmap-innovations"},"title":"Akoya Biosciences Unveils Comprehensive Roadmap of Innovations at Inaugural Spatial Day Event","type":{"title":"General","id":3886},"teaser":"-Company previews an integrated suite of solutions, including the new PhenoCycler ™ -Fusion System  for unbiased spatial discovery, at unprecedented speeds -Innovations include a novel spatial transcriptomics chemistry and universal protein chemistry for accelerated biomarker discovery and","language":"en","releaseDate":{"dateUTC":"2021-12-15T17:00:07","date":"2021-12-15T12:00:07","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Unveils Comprehensive Roadmap of Innovations at Inaugural Spatial Day Event","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7266/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-12-15T17:00:18","lastUpdatedUTC":"2021-12-15T17:00:18"},{"id":7236,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7236","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-groundbreaking-collaboration-pathai"},"title":"Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers","type":{"title":"General","id":3886},"teaser":"Partnership pairs Akoya’s spatial phenotyping solutions and PathAI’s AI-based algorithms to elucidate spatial biomarker signatures for biopharma partners MARLBOROUGH, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company ® , and PathAI, a","language":"en","releaseDate":{"dateUTC":"2021-12-13T13:05:29","date":"2021-12-13T08:05:29","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7236/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-12-13T13:05:39","lastUpdatedUTC":"2021-12-13T13:05:39"},{"id":7221,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7221","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-secures-clia-lab-certification-milestone"},"title":"Akoya Biosciences Secures CLIA Lab Certification, a Milestone for Applying Its Spatial Biology Technologies to Accelerating Precision Cancer Therapies","type":{"title":"General","id":3886},"teaser":"Certification ensures Akoya’s cutting-edge spatial biology tools meet the highest standards for translational medicine and clinical research, with longer term potential for companion diagnostics. MARLBOROUGH, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The","language":"en","releaseDate":{"dateUTC":"2021-11-30T13:05:28","date":"2021-11-30T08:05:28","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Secures CLIA Lab Certification, a Milestone for Applying Its Spatial Biology Technologies to Accelerating Precision Cancer Therapies","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7221/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-30T13:05:32","lastUpdatedUTC":"2021-11-30T13:05:32"},{"id":7206,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7206","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-host-inaugural-spatial-day-december-15-2021"},"title":"Akoya Biosciences to Host Inaugural Spatial Day on December 15, 2021","type":{"title":"General","id":3886},"teaser":"The program will highlight the latest breakthroughs and applications in spatial biology and the company’s latest innovations to accelerate breakthroughs in discovery and clinical research. MARLBOROUGH, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc.","language":"en","releaseDate":{"dateUTC":"2021-11-22T13:05:31","date":"2021-11-22T08:05:31","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Host Inaugural Spatial Day on December 15, 2021","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7206/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-22T13:05:42","lastUpdatedUTC":"2021-11-22T13:05:42"},{"id":7176,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7176","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-third-quarter-2021-financial-results-and-issues"},"title":"Akoya Reports Third Quarter 2021 Financial Results and Issues Full Year 2021 Guidance","type":{"title":"General","id":3886},"teaser":"Q3 revenue $13.5 million, the highest in Akoya’s history and an increase of 35% over prior year MARLBOROUGH, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending","language":"en","releaseDate":{"dateUTC":"2021-11-08T21:05:58","date":"2021-11-08T16:05:58","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports Third Quarter 2021 Financial Results and Issues Full Year 2021 Guidance","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7176/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-08T21:06:13","lastUpdatedUTC":"2021-11-08T21:06:13"},{"id":7166,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7166","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-present-data-sitc-2021-highlighting-novel"},"title":"Akoya Biosciences to Present Data at SITC 2021 Highlighting Novel Spatial Biology Applications","type":{"title":"General","id":3886},"teaser":"Presentations by the company and customers will offer insights on how spatial phenotypic signatures can accelerate immuno-oncology biomarker development MARLBOROUGH, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that","language":"en","releaseDate":{"dateUTC":"2021-11-04T12:05:29","date":"2021-11-04T08:05:29","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Present Data at SITC 2021 Highlighting Novel Spatial Biology Applications","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7166/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-04T12:05:39","lastUpdatedUTC":"2021-11-04T12:05:39"},{"id":7156,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7156","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-participate-two-upcoming-investor-conferences-november"},"title":"Akoya to Participate at Two Upcoming Investor Conferences in November","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will be virtually participating in two upcoming investor conferences. Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health &","language":"en","releaseDate":{"dateUTC":"2021-11-03T12:01:09","date":"2021-11-03T08:01:09","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Participate at Two Upcoming Investor Conferences in November","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7156/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-03T12:01:15","lastUpdatedUTC":"2021-11-04T17:34:31"},{"id":7136,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7136","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-founding-members-first-its-kind"},"title":"Akoya Biosciences Announces Founding Members of First-of-its-Kind Imaging Innovators (I²) Network","type":{"title":"General","id":3886},"teaser":"I 2 Investigators will leverage CODEX technology and the expertise of Akoya and its partners as they push the boundaries of spatial biology. MARLBOROUGH, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company ® , today announced the first members","language":"en","releaseDate":{"dateUTC":"2021-11-02T12:05:27","date":"2021-11-02T08:05:27","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Founding Members of First-of-its-Kind Imaging Innovators (I²) Network","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7136/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-02T12:05:31","lastUpdatedUTC":"2021-11-02T12:05:31"},{"id":7116,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7116","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-appoints-pascal-bamford-phd-svp-rd-and"},"title":"Akoya Biosciences Appoints Pascal Bamford, PhD, as SVP, R&D and Laboratory Operations","type":{"title":"General","id":3886},"teaser":"Accomplished leader in laboratory innovations and diagnostics MARLBOROUGH, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced the appointment of Pascal Bamford, PhD, as Senior Vice President, Research and","language":"en","releaseDate":{"dateUTC":"2021-10-26T12:05:29","date":"2021-10-26T08:05:29","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Appoints Pascal Bamford, PhD, as SVP, R&D and Laboratory Operations","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7116/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-10-26T12:05:40","lastUpdatedUTC":"2021-10-26T12:05:40"},{"id":7091,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7091","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-third-quarter-2021-financial-results-november-8th"},"title":"Akoya to Report Third Quarter 2021 Financial Results on November 8th, 2021","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of 2021 after the market close on Monday, November 8 th , 2021.","language":"en","releaseDate":{"dateUTC":"2021-10-19T12:05:30","date":"2021-10-19T08:05:30","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report Third Quarter 2021 Financial Results on November 8th, 2021","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7091/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-10-19T12:05:37","lastUpdatedUTC":"2021-10-19T12:05:37"},{"id":7071,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7071","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-appoints-diagnostics-industry-pioneer-myla-lai"},"title":"Akoya Biosciences Appoints Diagnostics Industry Pioneer Myla Lai-Goldman, MD, to its Board of Directors","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Myla Lai-Goldman, MD, a true pioneer and leader in the diagnostic industry, to its board of directors.","language":"en","releaseDate":{"dateUTC":"2021-09-22T12:05:28","date":"2021-09-22T08:05:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Appoints Diagnostics Industry Pioneer Myla Lai-Goldman, MD, to its Board of Directors","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7071/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-09-22T12:05:35","lastUpdatedUTC":"2021-09-22T12:05:35"},{"id":7041,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7041","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-present-morgan-stanley-19th-annual-global"},"title":"Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Morgan Stanley 19th Annual Global Healthcare Conference.","language":"en","releaseDate":{"dateUTC":"2021-08-31T12:05:07","date":"2021-08-31T08:05:07","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/7041/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-31T12:05:09","lastUpdatedUTC":"2021-08-31T12:05:09"},{"id":6996,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6996","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-53-revenue-growth-second-quarter-2021"},"title":"Akoya Reports 53% Revenue Growth in the Second Quarter of 2021","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the second quarter ending June 30, 2021. Second Quarter Financial Highlights Total revenue for the second quarter of 2021","language":"en","releaseDate":{"dateUTC":"2021-08-10T20:05:12","date":"2021-08-10T16:05:12","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports 53% Revenue Growth in the Second Quarter of 2021","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6996/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-10T20:05:21","lastUpdatedUTC":"2021-08-10T20:05:21"},{"id":6971,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6971","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-present-canaccord-41st-annual-growth"},"title":"Akoya Biosciences to Present at the Canaccord 41st Annual Growth Conference","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will be virtually participating in the Canaccord 41st Annual Growth Conference. Brian McKelligon, CEO is scheduled to present on Wednesday,","language":"en","releaseDate":{"dateUTC":"2021-08-03T12:05:29","date":"2021-08-03T08:05:29","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Present at the Canaccord 41st Annual Growth Conference","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6971/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-03T12:05:30","lastUpdatedUTC":"2021-08-03T12:05:30"},{"id":6961,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6961","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-second-quarter-2021-financial-results-august-10"},"title":"Akoya to Report Second Quarter 2021 Financial Results on August 10, 2021","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the second quarter of 2021 after the market close on Tuesday, August 10, 2021.","language":"en","releaseDate":{"dateUTC":"2021-07-20T12:05:11","date":"2021-07-20T08:05:11","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report Second Quarter 2021 Financial Results on August 10, 2021","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6961/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-07-20T12:05:22","lastUpdatedUTC":"2021-07-20T12:05:22"},{"id":6951,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6951","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-announces-publication-mitre-study-first-multi"},"title":"Akoya Announces Publication of the MITRE Study, the First Multi-Institutional Analytical Demonstration of a Spatial Biology Workflow, in the Journal for ImmunoTherapy of Cancer","type":{"title":"General","id":3886},"teaser":"Results from the study provide evidence of standardization of an automated spatial biology workflow, based on the company’s Phenoptics™ multiplex immunofluorescence (mIF) platform, for clinical and translational research MARLBOROUGH, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc.,","language":"en","releaseDate":{"dateUTC":"2021-07-19T12:05:28","date":"2021-07-19T08:05:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Announces Publication of the MITRE Study, the First Multi-Institutional Analytical Demonstration of a Spatial Biology Workflow, in the Journal for ImmunoTherapy of Cancer","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6951/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-07-19T12:05:29","lastUpdatedUTC":"2021-07-19T12:05:29"},{"id":6931,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6931","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-partner-nikon-crestoptics-and-andor-enable-new-spatial"},"title":"Akoya to Partner with Nikon, CrestOptics and Andor to Enable New Spatial Biology Applications through the Imaging Innovators (I²) Network","type":{"title":"General","id":3886},"teaser":"Company plans to work with multiple microscope partners to broaden access to the CODEX® solution for single-cell, multiplexed imaging MARLBOROUGH, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced partnerships with premier","language":"en","releaseDate":{"dateUTC":"2021-06-29T12:05:48","date":"2021-06-29T08:05:48","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Partner with Nikon, CrestOptics and Andor to Enable New Spatial Biology Applications through the Imaging Innovators (I²) Network","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6931/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-29T12:05:56","lastUpdatedUTC":"2021-06-29T23:17:48"},{"id":6906,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6906","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-appoints-diagnostics-industry-leader-scott"},"title":"Akoya Biosciences Appoints Diagnostics Industry Leader Scott Mendel to its Board of Directors","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (NASDAQ: AKYA), The Spatial Biology Company ® , today announced the appointment of diagnostics industry leader Scott Mendel to its board of directors. “I am delighted to join the board of directors of Akoya, a company","language":"en","releaseDate":{"dateUTC":"2021-06-25T12:05:27","date":"2021-06-25T08:05:27","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Appoints Diagnostics Industry Leader Scott Mendel to its Board of Directors","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6906/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-25T12:05:38","lastUpdatedUTC":"2021-06-25T12:05:38"},{"id":6881,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6881","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-help-support-leading-philanthropic-organization-spatial"},"title":"Akoya to Help Support Leading Philanthropic Organization with Spatial Phenotyping Capabilities","type":{"title":"General","id":3886},"teaser":"CODEX’s single-cell, multiplex imaging capabilities to be included in Chan Zuckerberg Initiative grantee toolkit to help fuel the next wave of biological discoveries MARLBOROUGH, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA) The Spatial Biology Company ® , today","language":"en","releaseDate":{"dateUTC":"2021-06-15T12:05:29","date":"2021-06-15T08:05:29","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Help Support Leading Philanthropic Organization with Spatial Phenotyping Capabilities","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6881/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-15T12:05:39","lastUpdatedUTC":"2021-06-15T12:05:39"},{"id":6766,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6766","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-announces-publication-new-immunotherapy-biomarker"},"title":"Akoya Announces Publication of New Immunotherapy Biomarker Signature in Science, Leveraging Principles of Astronomy and Pathology","type":{"title":"General","id":3886},"teaser":"Investigators at Johns Hopkins University (JHU) used AstroPath to identify and validate biomarkers for accurate prediction of long-term response to immune checkpoint inhibitors in advanced melanoma AstroPath combines JHU’s famed 3D sky mapping algorithms for managing astronomical-scale datasets","language":"en","releaseDate":{"dateUTC":"2021-06-10T18:00:08","date":"2021-06-10T14:00:08","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Announces Publication of New Immunotherapy Biomarker Signature in Science, Leveraging Principles of Astronomy and Pathology","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6766/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-10T18:00:19","lastUpdatedUTC":"2021-06-10T18:00:19"},{"id":6736,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6736","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-set-join-russell-3000r-index"},"title":"Akoya Set to Join Russell 3000® Index","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, is set to join the broad-market Russell 3000 ®  Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on","language":"en","releaseDate":{"dateUTC":"2021-06-09T12:02:30","date":"2021-06-09T08:02:30","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Set to Join Russell 3000® Index","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6736/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-09T12:02:33","lastUpdatedUTC":"2021-06-09T12:02:33"},{"id":6721,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6721","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-and-astrazeneca-collaborate-spatial-biology-approach"},"title":"Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology","type":{"title":"General","id":3886},"teaser":"Partnership aims to leverage spatial biology data, generated on Akoya’s Phenoptics™ platform, to inform and guide drug development programs MARLBOROUGH, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA) The Spatial Biology Company ® , today announced a collaboration","language":"en","releaseDate":{"dateUTC":"2021-06-04T12:05:10","date":"2021-06-04T08:05:10","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6721/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-04T12:05:12","lastUpdatedUTC":"2021-06-04T12:05:12"},{"id":6711,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6711","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-announces-rollout-strategic-clinical-research-program"},"title":"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications","type":{"title":"General","id":3886},"teaser":"Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials MARLBOROUGH, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company ® , today","language":"en","releaseDate":{"dateUTC":"2021-06-02T12:05:07","date":"2021-06-02T08:05:07","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6711/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-02T12:05:12","lastUpdatedUTC":"2021-06-02T12:05:12"},{"id":6656,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6656","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-reports-first-quarter-2021-financial-results-and-issues"},"title":"Akoya Reports First Quarter 2021 Financial Results and Issues Full Year 2021 Guidance","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2021. First Quarter Financial Highlights: Total revenue for the first quarter of 2021 was","language":"en","releaseDate":{"dateUTC":"2021-05-18T20:05:35","date":"2021-05-18T16:05:35","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Reports First Quarter 2021 Financial Results and Issues Full Year 2021 Guidance","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6656/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-18T20:05:44","lastUpdatedUTC":"2021-05-18T20:05:44"},{"id":6646,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6646","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-and-zeiss-co-market-innovative-codexr-spatial-biology"},"title":"Akoya and ZEISS to Co-Market Innovative CODEX® Spatial Biology Workflow","type":{"title":"General","id":3886},"teaser":"The partnership brings together one of the world’s premier microscopy vendors and Akoya’s high-parameter CODEX® System for advancing the emerging field of spatial phenotyping and discovery MARLBOROUGH, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial","language":"en","releaseDate":{"dateUTC":"2021-05-17T12:05:10","date":"2021-05-17T08:05:10","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya and ZEISS to Co-Market Innovative CODEX® Spatial Biology Workflow","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6646/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-17T12:05:30","lastUpdatedUTC":"2021-05-17T12:05:30"},{"id":6621,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6621","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-report-first-quarter-2021-financial-results-may-18-2021"},"title":"Akoya to Report First Quarter 2021 Financial Results on May 18, 2021","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021.","language":"en","releaseDate":{"dateUTC":"2021-05-12T12:05:33","date":"2021-05-12T08:05:33","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Report First Quarter 2021 Financial Results on May 18, 2021","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6621/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-12T12:05:37","lastUpdatedUTC":"2021-05-12T12:05:37"},{"id":6606,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6606","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-begins-accepting-applications-first-its-kind"},"title":"Akoya Biosciences Begins Accepting Applications for First-of-its-Kind Imaging Innovators (I²) Network","type":{"title":"General","id":3886},"teaser":"Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system’s open, accessible interface MARLBOROUGH, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that its","language":"en","releaseDate":{"dateUTC":"2021-05-11T12:03:23","date":"2021-05-11T08:03:23","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Begins Accepting Applications for First-of-its-Kind Imaging Innovators (I²) Network","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6606/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-11T12:03:24","lastUpdatedUTC":"2021-05-11T12:03:24"},{"id":6526,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6526","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-announces-closing-initial-public-offering-and-full"},"title":"Akoya Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced the closing of its initial public offering of 7,567,000 shares of its common stock, including the exercise in full by the underwriters of their","language":"en","releaseDate":{"dateUTC":"2021-04-20T20:05:35","date":"2021-04-20T16:05:35","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6526/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-20T20:05:41","lastUpdatedUTC":"2021-04-20T20:05:41"},{"id":6501,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6501","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-announces-pricing-initial-public-offering"},"title":"Akoya Biosciences Announces Pricing of Initial Public Offering","type":{"title":"General","id":3886},"teaser":"MARLBOROUGH, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its initial public offering of 6,580,000 shares of its common stock at a price of $20.00 per share, for gross proceeds of $131.6","language":"en","releaseDate":{"dateUTC":"2021-04-16T02:00:28","date":"2021-04-15T22:00:28","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Announces Pricing of Initial Public Offering","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6501/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-16T02:00:33","lastUpdatedUTC":"2021-04-16T02:00:33"},{"id":6481,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6481","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-appoints-industry-leader-frederic-pla-chief-operating"},"title":"Akoya Appoints Industry Leader Frederic Pla as Chief Operating Officer to Spearhead Growth Initiatives","type":{"title":"General","id":3886},"teaser":"Accomplished executive brings deep scientific and operational expertise Marlborough, MA. — April 5, 2021 — Akoya Biosciences, Inc., The Spatial Biology Company®, today announced the appointment of Frederic Pla, PhD, as Chief Operating Officer. Dr. Pla will play a key role in preparing the company","language":"en","releaseDate":{"dateUTC":"2021-04-05T12:00:00","date":"2021-04-05T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Appoints Industry Leader Frederic Pla as Chief Operating Officer to Spearhead Growth Initiatives","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6481/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-13T13:35:24","lastUpdatedUTC":"2021-04-13T13:42:08"},{"id":6486,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6486","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-help-support-human-cell-atlas-hca-initiative-single-cell"},"title":"Akoya to Help Support the Human Cell Atlas (HCA) Initiative with Single-Cell, Spatial Imaging Capabilities","type":{"title":"General","id":3886},"teaser":"CODEX’s spatial phenotyping capabilities will contribute to HCA investigators’ ability to build comprehensive tissue maps. MARLBOROUGH, Mass. — March 23, 2021 — Akoya Biosciences, Inc., The Spatial Biology Company®, today announced its support for the Human Cell Atlas (HCA) initiative, offering the","language":"en","releaseDate":{"dateUTC":"2021-03-23T12:00:00","date":"2021-03-23T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya to Help Support the Human Cell Atlas (HCA) Initiative with Single-Cell, Spatial Imaging Capabilities","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6486/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-13T13:44:31","lastUpdatedUTC":"2021-04-13T13:52:49"},{"id":6421,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6421","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-and-johns-hopkins-collaborative-agreement-supports"},"title":"Akoya and Johns Hopkins’ Collaborative Agreement Supports Pioneering New Approach to Immunotherapy Biomarker Discovery and Validation","type":{"title":"General","id":3886},"teaser":"Astronomy and Pathology (AstroPath™) come together for the first time to discover and clinically validate new spatial phenotypic signatures using multiplex immunofluorescence. MARLBOROUGH, Mass. — March 2, 2021   —  Akoya Biosciences, Inc., The Spatial Biology Company®, today announced a","language":"en","releaseDate":{"dateUTC":"2021-03-02T05:00:00","date":"2021-03-02T00:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya and Johns Hopkins’ Collaborative Agreement Supports Pioneering New Approach to Immunotherapy Biomarker Discovery and Validation","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6421/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-04T05:27:06","lastUpdatedUTC":"2021-03-04T05:28:02"},{"id":6406,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6406","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-present-39th-annual-jp-morgan-healthcare"},"title":"Akoya Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021","type":{"title":"General","id":3886},"teaser":"MENLO PARK, Calif. — January 11, 2021  — Akoya Biosciences, Inc., The Spatial Biology Company®, today announced that Brian McKelligon, the company’s Chief Executive Officer, is scheduled to present at the J.P. Morgan 39th Annual Healthcare Conference on Wednesday, January 13, 2021. Mr.","language":"en","releaseDate":{"dateUTC":"2021-01-11T05:00:00","date":"2021-01-11T00:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6406/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-02T05:41:46","lastUpdatedUTC":"2021-03-02T05:42:40"},{"id":6401,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6401","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoyas-codexr-system-utilized-novel-study-muscle-strength-and"},"title":"Akoya’s CODEX® System Utilized in Novel Study of Muscle Strength and Aging Published in Science","type":{"title":"General","id":3886},"teaser":"The CODEX ®  system enables Stanford researchers to study spatial localization and cellular phenotypes associated with a novel protein implicated in aging. MARLBOROUGH, Mass. — December 11, 2020   — Akoya Biosciences, Inc., The Spatial Biology Company®, today announced that CODEX was used for","language":"en","releaseDate":{"dateUTC":"2020-12-11T05:00:00","date":"2020-12-11T00:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya’s CODEX® System Utilized in Novel Study of Muscle Strength and Aging Published in Science","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6401/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-02T05:40:32","lastUpdatedUTC":"2021-03-02T05:41:37"},{"id":6396,"link":{"url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6396","hostedUrl":"http://investors.akoyabio.com/news-releases/news-release-details/akoya-biosciences-receives-iso-134852016-quality-certification"},"title":"Akoya Biosciences Receives ISO 13485:2016 Quality Certification","type":{"title":"General","id":3886},"teaser":"Akoya demonstrates ability to meet regulatory requirements for the development and production of medical-grade devices and related products MARLBOROUGH, Mass. — October 13, 2020   —  Akoya Biosciences, Inc., The Spatial Biology Company®, today announced that the company received ISO 13485:2016","language":"en","releaseDate":{"dateUTC":"2020-10-13T04:00:00","date":"2020-10-13T00:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Akoya Biosciences Receives ISO 13485:2016 Quality Certification","url":"https://clientapi.gcs-web.com/data/f2609b82-c986-47cd-8046-d09385a25d79/news/6396/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-02T05:39:25","lastUpdatedUTC":"2021-03-02T05:40:24"}],"error":null}